In another big win for the Columbus Region, American Regent, Inc., a Daiichi Sankyo Group company, has chosen to strengthen its footprint in New Albany. A new multi-million-dollar expansion will create more job opportunities, allowing for the pharmaceutical company to better utilize our region’s logistical advantages to grow and serve more patients.

American Regent is a leader in developing and delivering complex, hard-to-manufacture injectables and drug shortage products. Through this latest expansion project at its existing facility in New Albany, the company is now positioned to produce a new, life-saving oncology drug in the Ohio area. The physical expansion will grow the existing building and modernize the current facility.

“We are excited to expand our presence in the Columbus Region,” said Paul Diolosa, President & CEO of American Regent. “The region’s supportive business environment, exceptional talent pool, and strategic location have been instrumental in our success. This expansion not only allows us to increase our production capabilities, but also continue delivering critical medications to patients who need them.”

The Columbus Region’s growing life sciences sector is characterized by robust investment, strategic partnerships, and a strong talent pipeline, all of which are contributing to its prominence in the pharmaceutical and biotechnology industries.

“We are thrilled to see American Regent expanding their operations here,” said New Albany Mayor Sloan Spalding. “Our community has made a point of welcoming innovative companies into this region, and American Regent continues to positively impact our local economy with its significant investments in innovative pharmaceutical manufacturing.”

“American Regent’s investment reflects Ohio’s position as a leading hub for pharmaceutical manufacturing,” said JobsOhio President and CEO J.P. Nauseef. “This expansion will not only create jobs but also advance healthcare infrastructure and economic resilience in the region.”